Potentiation of antitumor activity of irinotecan by chemically modified oligonucleotides.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  International Journal of Oncology

• Publication date

  2001-05-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3892/IJO.18.5.1061PMID 11295057
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antitumor activity of a camptothecin derivative, CPT-11, against human tumor xenografts in nude mice

  2004cited by this paper
• Antisense therapeutics: is it as simple as complementary base recognition?

  2000cited by this paper
• Antitumor activity and pharmacokinetics of a mixed-backbone antisense oligonucleotide targeted to the RIalpha subunit of protein kinase A after oral administration.

  1999cited by this paper
• Antisense down‐regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5‐FUdR, 5‐FU and Tomudex in HeLa cells

  1999cited by this paper
• Inhibition of cyclin D1 expression in human pancreatic cancer cells is associated with increased chemosensitivity and decreased expression of multiple chemoresistance genes.

  1999cited by this paper
• Importance of nucleotide sequence and chemical modifications of antisense oligonucleotides.

  1999cited by this paper
• Cooperative inhibitory effect of novel mixed backbone oligonucleotide targeting protein kinase A in combination with docetaxel and anti-epidermal growth factor-receptor antibody on human breast cancer cell growth.

  1999cited by this paper
• Topoisomerase I inhibitors in the treatment of colorectal cancer.

  1999cited by this paper
• MDM2 oncogene as a target for cancer therapy: An antisense approach.

  1999cited by this paper
• Synergistic antitumor effects of HER2/neu antisense oligodeoxynucleotides and conventional chemotherapeutic agents.

  1999cited by this paper
• Synergistic cytotoxicity of bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines.

  1998cited by this paper
• Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.

  1998cited by this paper
• CPT-11 sensitivity in relation to the expression of P170-glycoprotein and multidrug resistance-associated protein.

  1998cited by this paper
• Nucleic acid therapeutics: state of the art and future prospects.

  1998cited by this paper
• Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage.

  1998cited by this paper
• Pharmacology of irinotecan.

  1998cited by this paper
• Irinotecan: A New Antineoplastic Agent for the Management of Colorectal Cancer

  1998cited by this paper
• Synergistic inhibition of human cancer cell growth by cytotoxic drugs and mixed backbone antisense oligonucleotide targeting protein kinase A.

  1997cited by this paper
• In vivo stability, disposition and metabolism of a "hybrid" oligonucleotide phosphorothioate in rats.

  1995cited by this paper
• Activity of CPT-11 (irinotecan hydrochloride), a topoisomerase I inhibitor, against human tumor colony-forming units.

  1994cited by this paper

• Hdm2 is regulated by K-Ras and mediates p53-independent functions in pancreatic cancer cells

  2009cites this paper
• Prognostic and predictive markers in radiation therapy: focus on prostate cancer.

  2008cites this paper
• Antisense-MDM2 sensitizes LNCaP prostate cancer cells to androgen deprivation, radiation, and the combination in vivo.

  2007cites this paper
• ANTISENSE STRATEGIES FOR THE DEVELOPMENT OF NOVEL CANCER THERAPEUTICS

  2006cites this paper
• Antisense-based cancer therapeutics: are we there yet?

  2006cites this paper
• Antisense approaches in drug discovery and development.

  2005cites this paper
• Sensitization of Prostate Cancer Cells to Androgen Deprivation and Radiation via Manipulation of the MDM2 Pathway

  2005cites this paper
• Cooperative inhibitory effects of antisense oligonucleotide of cell adhesion molecules and cimetidine on cancer cell adhesion.

  2004cites this paper
• Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.

  2004cites this paper
• The analysis of pyridylamino-dextran sulfate oligomers by high-performance liquid chromatography and a novel detection system for sulfated polysaccharides.

  2004cites this paper
• Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.

  2003cites this paper
• Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination.

  2003cites this paper
• Increase in Therapeutic Index of Doxorubicin and Vinblastine by Aptameric Oligonucleotide in Human T Lymphoblastic Drug-Sensitive and Multidrug-Resistant Cells

  2002cites this paper
• Antisense MDM2 oligonucleotides restore the apoptotic response of prostate cancer cells to androgen deprivation

  2002cites this paper
• GEM 231, a second-generation antisense agent complementary to protein kinase A RIalpha subunit, potentiates antitumor activity of irinotecan in human colon, pancreas, prostate and lung cancer xenografts.

  2002cites this paper
• The Cockayne syndrome group B DNA repair protein as an anti-cancer target.

  2001cites this paper
• Antisense and/or immunostimulatory oligonucleotide therapeutics.

  2001cites this paper